- NEWS AND VIEWS
Targeting RNA opens therapeutic avenues for Timothy syndrome
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 628, 730-732 (2024)
doi: https://doi.org/10.1038/d41586-024-00911-1
References
Chen, X. et al. Nature 628, 818–825 (2024).
Splawski, I. et al. Cell 119, 19–31 (2004).
Tang, Z. Z. et al. J. Biol. Chem. 286, 10007–10016 (2011).
Birey, F. et al. Cell Stem Cell 29, 248–264 (2022).
Revah, O. et al. Nature 610, 319–326 (2022).
McCauley, M. E. & Bennett, C. F. Neuron 111, 2465–2468 (2023).
Gandal, M. J. et al. Science 362, eaat8127 (2018).
Panagiotakos, G. et al. eLife 8, e51037 (2019).
Dowden, H. & Munro, J. Nature Rev. Drug Discov. 18, 495–496 (2019).
Adashi, E. Y., O’Mahony, D. P. & Cohen, I. G. Am. J. Med. 136, 853–854 (2023).
Dulla, K. et al. Mol. Ther. Nucleic Acids 12, 730–740 (2018).
Russell, S. R. et al. Nature Med. 28, 1014–1021 (2022).
Competing Interests
The author declares no competing interests.